Addyi vs Low-Dose Testosterone for Women: A Special Populations Head-to-Head

What Is Each Drug and How Does It Work?

These two treatments take completely different biological routes to the same destination: more satisfying sexual desire for women who have lost it. Knowing the mechanism matters because it predicts who responds and who doesn't.

Addyi (Flibanserin): A Brain-Based Approach

Flibanserin is a non-hormonal, centrally acting agent that acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist. It also has modest activity at dopamine D4 receptors. The net effect is a shift in the brain's neurochemical balance toward dopamine and norepinephrine, which are broadly associated with motivation and desire, and away from the serotonin-heavy state that suppresses it.

The FDA approved Addyi in August 2015 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The label is narrow on purpose. Clinical trials enrolled almost exclusively premenopausal, naturally cycling women, so the approval does not extend to postmenopausal women or to women taking hormonal contraception without specific guidance.

Low-Dose Testosterone: A Hormonal Approach

Testosterone is the most abundant bioactive sex steroid in women across the entire lifespan, though most people don't know that. Women produce testosterone in the ovaries and adrenal glands, and serum levels drop substantially after oophorectomy, during the menopause transition, and with age. Low-dose transdermal testosterone attempts to restore levels to the upper end of the normal premenopausal physiologic range, roughly 0.5 to 2.4 nmol/L total testosterone.

There is no FDA-approved testosterone product for women in the United States. Compounded transdermal creams, gels, or modified versions of male patches cut to deliver female-appropriate doses are what clinicians actually prescribe. The 2019 Global Consensus Statement on the Use of Testosterone Therapy for Women, endorsed by the International Society for the Study of Women's Sexual Health and The Menopause Society, concluded that transdermal testosterone improves HSDD in postmenopausal women, based on a systematic review of 36 randomized controlled trials.

Efficacy: What Do the Trials Actually Show?

Both drugs work. The effect sizes are modest, and the populations studied are different, which makes direct comparison genuinely difficult.

Addyi's Trial Evidence

The BEGONIA trial, a phase 3 randomized controlled trial published in the Journal of Sexual Medicine in 2014, enrolled 1,378 premenopausal women with HSDD and demonstrated that flibanserin 100 mg nightly significantly increased the number of satisfying sexual events (SSEs), reduced distress, and improved desire scores on the Female Sexual Function Index (FSFI) compared to placebo. The effect on SSEs was approximately 0.5 to 1 additional satisfying event per month above placebo, a statistically real but clinically modest difference.

Three other phase 3 trials (DAISY, VIOLET, and SUNFLOWER) confirmed similar findings. Women who saw improvement generally noticed it within 4 to 8 weeks. About 10% discontinued due to side effects, most commonly dizziness, somnolence, and nausea.

Testosterone's Trial Evidence

The 2019 Global Consensus pooled data from 36 RCTs and concluded that transdermal testosterone at physiologic doses significantly improves sexual function scores, frequency of satisfying sexual activity, and self-reported desire in postmenopausal women. The most-studied product was a 300 mcg/day testosterone patch (Intrinsa, never approved in the US), which showed consistent benefit across multiple populations. Effect sizes were similar to or larger than those seen with flibanserin in comparable trials, though again, direct comparison in a single study does not exist.

A framework for choosing between them by life stage:

| Life Stage | Preferred First-Line Option | Notes | |---|---|---| | Premenopausal, cycling | Addyi (flibanserin) | Only FDA-approved option for this group | | Perimenopause | Testosterone off-label; Addyi possible | Hormonal flux makes response to Addyi less predictable | | Postmenopause (natural) | Testosterone | Strongest evidence base; Addyi not approved for this group | | Surgical menopause (oophorectomy) | Testosterone | Abrupt androgen loss makes testosterone physiologically rational | | PCOS | Addyi preferred if androgens are elevated | Baseline hyperandrogenism may make testosterone inappropriate | | On combined oral contraceptives | Addyi requires caution; testosterone off-label | OCs raise SHBG, suppressing free testosterone further |

Head-to-Head in Special Populations

This is where the comparison gets clinically meaningful. Most articles treat HSDD as a single condition. It isn't.

Surgical Menopause and Oophorectomy

Women who undergo bilateral oophorectomy lose up to 50% of their circulating testosterone almost overnight. This is the population with the most biologically intuitive case for testosterone replacement. The Global Consensus Statement specifically identifies surgically menopausal women as a group likely to benefit from transdermal testosterone, noting that the evidence is consistent across this subgroup.

Addyi has no data in surgically menopausal women and is not approved for postmenopausal women of any kind. In this population, testosterone is the clear choice.

PCOS

PCOS is defined in part by androgen excess, though many women with PCOS simultaneously have low sexual desire, likely due to psychological burden, body image, relationship stress, and insulin resistance rather than androgen deficiency. Serum testosterone levels in women with PCOS are often already elevated or high-normal.

Adding exogenous testosterone to an androgen-excess state carries real risks: worsening hirsutism, acne, and potentially worsening insulin sensitivity at supraphysiologic levels. The 2019 Global Consensus explicitly recommends checking androgen levels before prescribing testosterone and cautions against use in women with pre-existing hyperandrogenism.

Flibanserin, being non-hormonal, sidesteps androgen status entirely and may be the safer first option in premenopausal women with PCOS and HSDD, provided the cause of low desire has been explored and is not purely situational or related to untreated PCOS symptoms like depression, fatigue, or pain.

Women on Antidepressants (SSRIs/SNRIs)

SSRI-induced sexual dysfunction, including low desire, is one of the most common and under-reported side effects of antidepressants. Up to 70% of women on SSRIs report some degree of sexual dysfunction. Because flibanserin's mechanism is partly serotonergic, combining it with SSRIs is not straightforward. The prescribing information does not list SSRIs as a hard contraindication, but the overlapping serotonergic activity warrants caution, and data on this combination is thin.

Testosterone does not interact with SSRIs mechanistically, and small studies suggest that transdermal testosterone may partially reverse SSRI-induced sexual dysfunction. This makes testosterone a more practical option in women who cannot or do not want to adjust their antidepressant regimen.

Perimenopause

Perimenopause is a particularly underserved zone. Flibanserin's label covers only premenopausal women (defined by regular menstrual cycles), so perimenopausal women with irregular cycles are technically outside the approved indication. Testosterone has better biological rationale here: ovarian function and androgen production are already declining, and adding physiologic testosterone makes mechanistic sense.

Clinically, many women in perimenopause also have genitourinary syndrome of menopause (GSM), mood changes, and sleep disruption all of which independently suppress desire. Addressing those with estrogen or progesterone may do more for desire than either Addyi or testosterone in some patients.

Side Effects and Safety: What Women Should Know

The safety profiles are distinct, and the practical day-to-day tolerability differs substantially.

Addyi Side Effects

The most common adverse effects from the BEGONIA trial were:

• Dizziness (11.4% vs. 2.2% placebo)
• Somnolence (11.2% vs. 2.9%)
• Nausea (10.4% vs. 3.9%)
• Fatigue

These peak in the first two weeks and often improve. Taking flibanserin at bedtime reduces the functional impact of sedation.

The most serious concern is hypotension and syncope when combined with alcohol. The FDA required a Risk Evaluation and Mitigation Strategy (REMS) program because of this interaction. Patients must sign a form acknowledging the alcohol restriction. The prescribing label warns that even moderate alcohol consumption within two hours of a dose can cause dangerous blood pressure drops and loss of consciousness.

Flibanserin is also metabolized by CYP3A4. Moderate-to-strong CYP3A4 inhibitors (fluconazole, some SSRIs, some hormonal contraceptives at certain doses, clarithromycin) can raise flibanserin plasma levels significantly, increasing hypotension risk. This is not a minor drug interaction.

Testosterone Side Effects

At physiologic doses, the most common side effects reported in trials are:

• Acne (more common when doses drift above physiologic range)
• Increased body or facial hair (hirsutism)
• Clitoral enlargement (usually reversible)
• Voice deepening (rare at physiologic doses, but generally irreversible if it occurs)

The Global Consensus concluded that transdermal testosterone at doses titrated to keep serum levels within the normal premenopausal range did not adversely affect lipid profiles, cardiovascular risk, or breast cancer risk based on current evidence. The consensus also noted that long-term data beyond 24 months are limited, which is an honest evidence gap worth naming.

Monitoring: baseline total testosterone (and ideally free testosterone), SHBG, hematocrit, lipids, and liver enzymes before starting, and repeat levels at 3 to 6 months to confirm you are in the physiologic range. Do not dose to supraphysiologic levels.

Pregnancy, Lactation, and Contraception Requirements

Both drugs are contraindicated in pregnancy. If there is any chance you could become pregnant, reliable contraception is required before starting either medication.

Addyi in Pregnancy and Lactation

Flibanserin has not been studied in pregnant women. Animal data showed adverse reproductive outcomes at doses that produce systemic exposure higher than the human therapeutic dose. The FDA label categorizes flibanserin as contraindicated in pregnancy, citing the absence of adequate human data and concerning animal findings.

Lactation: Flibanserin is excreted into rat milk. There are no human lactation studies. Given the lack of data and the drug's CNS activity, most clinicians advise against breastfeeding while taking flibanserin.

Addyi is approved only for premenopausal women, which means the prescribing clinician must confirm that reliable contraception is in place before starting treatment. Options that do not involve CYP3A4-inhibiting formulations are preferable given the drug interaction risk.

Testosterone in Pregnancy and Lactation

Testosterone is teratogenic. Androgen exposure during the first trimester of pregnancy can cause virilization of a female fetus, specifically ambiguous genitalia. This risk is biologically serious and not theoretical. The Global Consensus Statement explicitly states that testosterone therapy is contraindicated in women who are pregnant or trying to conceive.

Testosterone is detectable in breast milk. Exogenous androgens can suppress lactation by reducing prolactin-mediated milk production, and neonatal exposure through milk carries unknown but plausible developmental risks. Breastfeeding and testosterone use should not be combined.

For women trying to conceive, the combination of HSDD and fertility treatment is a genuine clinical scenario. Neither drug is appropriate during any fertility treatment cycle or during the luteal phase of a monitored cycle. Non-pharmacologic approaches (sex therapy, treatment of underlying depression or relationship factors, addressing pain or GSM) are the priority during this time.

Who This Is Right For (and Who It Is Not)

Addyi May Fit You Better If:

• You are premenopausal with regular cycles and diagnosed HSDD
• You have PCOS with elevated or normal-high androgens
• You prefer a non-hormonal mechanism
• You are not a regular alcohol drinker and are not on strong CYP3A4 inhibitors
• You want an FDA-approved option with formal prescribing oversight

Low-Dose Testosterone May Fit You Better If:

• You are postmenopausal (natural or surgical) with HSDD
• You had both ovaries removed and have noticed a sharp drop in desire since surgery
• You are on an SSRI and want to avoid additional serotonergic complexity
• You are perimenopausal with declining ovarian function
• Your baseline testosterone levels are in the low-to-normal range or below

Neither Option Is Appropriate If:

• You are pregnant, breastfeeding, or actively trying to conceive
• You have androgen-sensitive malignancy (e.g., certain breast or uterine cancers)
• Your low desire is entirely situational (new relationship stress, trauma, grief, untreated depression) without a clear physiologic component

Switching From Addyi to Low-Dose Testosterone

Some women start Addyi because they are premenopausal and then reach perimenopause or menopause while on it. The question of switching is common and under-discussed.

When to Consider a Switch

If you are currently on flibanserin and enter perimenopause or natural menopause, you are moving outside the population for which Addyi has evidence. The serotonin-dopamine mechanism may become less relevant if declining androgens are now the primary driver of low desire.

Signs that suggest a switch may make sense:

• Your HSDD symptoms are returning or worsening despite consistent Addyi use
• You have had your FSH and estradiol checked and you are clearly in the menopause range
• You are starting estrogen therapy for menopausal symptoms and want to address desire separately

How to Switch Safely

There is no pharmacokinetic reason to taper flibanserin slowly. You can stop it and begin testosterone after a washout of a few days. However, testosterone takes 4 to 12 weeks to show meaningful effect on desire, so managing expectations during the transition is important.

Before starting testosterone, check total testosterone, SHBG, free testosterone, hematocrit, and a lipid panel. This baseline matters for monitoring and for confirming the clinical picture matches androgen deficiency.

Dr. Rachel Goldberg, WomanRx board reviewer and ob-gyn specializing in sexual health, notes: "I often see women who have been on Addyi for years but entered menopause and wonder why it stopped working. The honest answer is that it was approved for premenopausal women, and their biology has changed. Testosterone is a more physiologically appropriate conversation at that point, though it requires careful monitoring and a frank discussion about the off-label status."

The Evidence Gap You Deserve to Know About

Both treatments have real evidence limitations for specific groups of women, and you deserve a straight answer about what is and is not known.

Flibanserin's trials enrolled almost no women of color as a proportion of the total sample, enrolled no postmenopausal women, and excluded women on antidepressants in most key trials. The effect size in the trials was modest: roughly 0.5 to 1 additional satisfying sexual event per 28-day period above placebo. Whether that is clinically meaningful is something you and your clinician need to judge together.

Testosterone's evidence is stronger in postmenopausal women than in premenopausal or perimenopausal women. The Global Consensus explicitly notes that evidence in premenopausal women is insufficient to support a recommendation. Cardiovascular and breast safety data beyond two years are limited. And because there is no FDA-approved female formulation, you are relying on compounding pharmacy quality, which varies.

Women have historically been under-enrolled in sexual health trials, and the available data is mostly industry-funded, with all the bias risk that entails. This does not mean the treatments do not work. It means the evidence is imperfect, and honest shared decision-making requires saying so.